Abstract
DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Epigenesis, Genetic / drug effects*
-
Gene Expression Regulation, Neoplastic / drug effects
-
Gene Targeting / methods
-
Histone Deacetylase Inhibitors / chemistry
-
Histone Deacetylase Inhibitors / pharmacology
-
Histone Deacetylase Inhibitors / therapeutic use*
-
Humans
-
Hydroxamic Acids / pharmacology
-
Hydroxamic Acids / therapeutic use
-
Medical Oncology / trends*
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Vorinostat
Substances
-
Antineoplastic Agents
-
Histone Deacetylase Inhibitors
-
Hydroxamic Acids
-
Vorinostat